English

INTELLIA THERAPEUTICS, INC.

EDGAR

NTLA Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 67.67M, using the latest reported figures. The previous period, 2024, was about USD 57.88M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

7.66 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 7659000 USD Source

Operating margin

-1,472.25%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -112760000 USD Source
Revenue: 7659000 USD Source

Operating cash flow

-83.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -200459000 USD Source
Operating Cash Flow: -117346000 USD Source

Free cash flow

-84.9 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -200459000 USD Source
Operating Cash Flow: -117346000 USD Source
Capital Expenditure: 1888000 USD Source
Capital Expenditure: 79000 USD Source

Cash and cash equivalents: 106 million USD 2026-06-30 Source
Exact value

106128000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 140 million shares 2026-06-30 Source
Exact value

140018200 shares

Reported share-count change

32.93% · 34.7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

105330693 shares · 2025-06-30· Source
140018200 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

59.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 13782000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 67671000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 44654000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 15048000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 7659000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-400 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -101324000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -412694000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -316908000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -96231000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -106634000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-347 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -325451000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -248552000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -394736000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -325451000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -117346000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -200459000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -117346000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

2.04 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 1003000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 974000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1129000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1003000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 79000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1888000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 79000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-349 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -325451000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -248552000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -394736000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -325451000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -117346000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -200459000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -117346000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1003000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 974000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1129000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 1003000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 79000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1888000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 79000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 10 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 10 of 11 periods available· newest 2025-12-31
Current liabilities: 10 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 10 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+16.9%

Prior period

USD 57.88 million

2024-01-01 – 2024-12-31
Current period

USD 67.67 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

67671000 − 57877000 = 9794000 USD

57877000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
67671000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Year-over-year change in Revenue: 9794000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 67671000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#1516895 Filing: 000119312526076550 Input fundies:Revenue: 57877000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#1518548 Filing: 000119312526076550
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 106.33 million

Prior period

−USD 519.02 million

2024-01-01 – 2024-12-31
Current period

−USD 412.69 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-412694000 − -519021000 = 106327000 USD

-519021000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-412694000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Year-over-year change in Net income: 106327000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -412694000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#3342755 Filing: 000119312526076550 Input fundies:NetIncome: -519021000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#3344503 Filing: 000119312526076550
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 45.86 million

Prior period

−USD 348.88 million

2024-01-01 – 2024-12-31
Current period

−USD 394.74 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-394736000 − -348880000 = -45856000 USD

-348880000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-394736000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Year-over-year change in Operating cash flow: -45856000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -394736000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2035094 Filing: 000119312526076550 Input fundies:OperatingCashFlow: -348880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2036985 Filing: 000119312526076550
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-80.5%

Prior period

USD 5.78 million

2024-01-01 – 2024-12-31
Current period

USD 1.13 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1129000 − 5778000 = -4649000 USD

5778000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1129000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Year-over-year change in Capital expenditure: -4649000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1129000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2044560 Filing: 000119312526076550 Input fundies:CapitalExpenditure: 5778000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2046336 Filing: 000119312526076550
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 67.67 million 100% of revenue
Operating costs Derived USD 508.66 million 752% of revenue
Operating income −USD 440.99 million −652% of revenue
Tax, interest and other Derived −USD 28.3 million −42% of revenue
Net income −USD 412.69 million −610% of revenue

Cash

Operating cash flow −USD 394.74 million −583% of revenue
Capital expenditure USD 1.13 million 1.7% of revenue
Free cash flow Derived −USD 395.87 million −585% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 295% of revenue.
2017 Operating loss: operating costs were 366% of revenue.
2018 Operating loss: operating costs were 399% of revenue.
2019 Operating loss: operating costs were 347% of revenue.
2020 Operating loss: operating costs were 336% of revenue.
2021 Operating loss: operating costs were 910% of revenue.
2022 Operating loss: operating costs were 979% of revenue.
2023 Operating loss: operating costs were 1,521% of revenue.
2024 Operating loss: operating costs were 1,023% of revenue.
2025 Operating loss: operating costs were 752% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	16479000	48638000 Derived	-32159000	-525000 Derived	-31634000	29944000 Derived	Source 2016-01-01 – 2016-12-31: 16479000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -32159000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -31634000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 36109000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 6165000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	26117000	95672000 Derived	-69555000	-2012000 Derived	-67543000	-75367000 Derived	Source 2017-01-01 – 2017-12-31: 26117000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -69555000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -67543000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -65276000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 10091000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	30434000	121304000 Derived	-90870000	-5527000 Derived	-85343000	-67615000 Derived	Source 2018-01-01 – 2018-12-31: 30434000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -90870000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -85343000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -61257000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 6358000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	43103000	149471000 Derived	-106368000	367818000 Derived	-474186000	-110034000 Derived	Source 2019-01-01 – 2019-12-31: 43103000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -106368000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -474186000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -103240000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 6794000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	57994000	194577000 Derived	-136583000	-2352000 Derived	-134231000	-53497000 Derived	Source 2020-01-01 – 2020-12-31: 57994000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -136583000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -134231000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -49912000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3585000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	33053000	300903000 Derived	-267850000	42000 Derived	-267892000	-237786000 Derived	Source 2021-01-01 – 2021-12-31: 33053000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -267850000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -267892000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -225030000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 12756000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	52121000	510285000 Derived	-458164000	16022000 Derived	-474186000	-346845000 Derived	Source 2022-01-01 – 2022-12-31: 52121000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -458164000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -474186000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -333287000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 13558000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	36275000	551566000 Derived	-515291000	-34099000 Derived	-481192000	-408071000 Derived	Source 2023-01-01 – 2023-12-31: 36275000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -515291000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -481192000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -394086000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 13985000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	57877000	592140000 Derived	-534263000	-15242000 Derived	-519021000	-354658000 Derived	Source 2024-01-01 – 2024-12-31: 57877000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -534263000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -519021000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -348880000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 5778000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	67671000	508661000 Derived	-440990000	-28296000 Derived	-412694000	-395865000 Derived	Source 2025-01-01 – 2025-12-31: 67671000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -440990000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -412694000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -394736000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1129000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 67.7M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	16479000	Revenue: 16479000 Open source
20172017-12-31	Revenue	26117000	Revenue: 26117000 Open source
20182018-12-31	Revenue	30434000	Revenue: 30434000 Open source
20192019-12-31	Revenue	43103000	Revenue: 43103000 Open source
20202020-12-31	Revenue	57994000	Revenue: 57994000 Open source
20212021-12-31	Revenue	33053000	Revenue: 33053000 Open source
20222022-12-31	Revenue	52121000	Revenue: 52121000 Open source
20232023-12-31	Revenue	36275000	Revenue: 36275000 Open source
20242024-12-31	Revenue	57877000	Revenue: 57877000 Open source
20252025-12-31	Revenue	67671000	Revenue: 67671000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

16.9% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 16479000 Open source
20172017-12-31	Year over year	58.5%	Revenue: 26117000 Open source Revenue: 16479000 Open source
20182018-12-31	Year over year	16.5%	Revenue: 30434000 Open source Revenue: 26117000 Open source
20192019-12-31	Year over year	41.6%	Revenue: 43103000 Open source Revenue: 30434000 Open source
20202020-12-31	Year over year	34.5%	Revenue: 57994000 Open source Revenue: 43103000 Open source
20212021-12-31	Year over year	-43%	Revenue: 33053000 Open source Revenue: 57994000 Open source
20222022-12-31	Year over year	57.7%	Revenue: 52121000 Open source Revenue: 33053000 Open source
20232023-12-31	Year over year	-30.4%	Revenue: 36275000 Open source Revenue: 52121000 Open source
20242024-12-31	Year over year	59.6%	Revenue: 57877000 Open source Revenue: 36275000 Open source
20252025-12-31	Year over year	16.9%	Revenue: 67671000 Open source Revenue: 57877000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -651.7% 2025

Net margin -609.9% 2025

Free cash flow margin -585% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-195.2%	Operating Income: -32159000 Open source Revenue: 16479000 Open source
20172017-12-31	Operating margin	-266.3%	Operating Income: -69555000 Open source Revenue: 26117000 Open source
20182018-12-31	Operating margin	-298.6%	Operating Income: -90870000 Open source Revenue: 30434000 Open source
20192019-12-31	Operating margin	-246.8%	Operating Income: -106368000 Open source Revenue: 43103000 Open source
20202020-12-31	Operating margin	-235.5%	Operating Income: -136583000 Open source Revenue: 57994000 Open source
20212021-12-31	Operating margin	-810.4%	Operating Income: -267850000 Open source Revenue: 33053000 Open source
20222022-12-31	Operating margin	-879%	Operating Income: -458164000 Open source Revenue: 52121000 Open source
20232023-12-31	Operating margin	-1,420.5%	Operating Income: -515291000 Open source Revenue: 36275000 Open source
20242024-12-31	Operating margin	-923.1%	Operating Income: -534263000 Open source Revenue: 57877000 Open source
20252025-12-31	Operating margin	-651.7%	Operating Income: -440990000 Open source Revenue: 67671000 Open source
20162016-12-31	Net margin	-192%	Net Income: -31634000 Open source Revenue: 16479000 Open source
20172017-12-31	Net margin	-258.6%	Net Income: -67543000 Open source Revenue: 26117000 Open source
20182018-12-31	Net margin	-280.4%	Net Income: -85343000 Open source Revenue: 30434000 Open source
20192019-12-31	Net margin	-1,100.1%	Net Income: -474186000 Open source Revenue: 43103000 Open source
20202020-12-31	Net margin	-231.5%	Net Income: -134231000 Open source Revenue: 57994000 Open source
20212021-12-31	Net margin	-810.5%	Net Income: -267892000 Open source Revenue: 33053000 Open source
20222022-12-31	Net margin	-909.8%	Net Income: -474186000 Open source Revenue: 52121000 Open source
20232023-12-31	Net margin	-1,326.5%	Net Income: -481192000 Open source Revenue: 36275000 Open source
20242024-12-31	Net margin	-896.8%	Net Income: -519021000 Open source Revenue: 57877000 Open source
20252025-12-31	Net margin	-609.9%	Net Income: -412694000 Open source Revenue: 67671000 Open source
20162016-12-31	Free cash flow margin	181.7%	Revenue: 16479000 Open source Operating Cash Flow: 36109000 Open source Capital Expenditure: 6165000 Open source
20172017-12-31	Free cash flow margin	-288.6%	Revenue: 26117000 Open source Operating Cash Flow: -65276000 Open source Capital Expenditure: 10091000 Open source
20182018-12-31	Free cash flow margin	-222.2%	Revenue: 30434000 Open source Operating Cash Flow: -61257000 Open source Capital Expenditure: 6358000 Open source
20192019-12-31	Free cash flow margin	-255.3%	Revenue: 43103000 Open source Operating Cash Flow: -103240000 Open source Capital Expenditure: 6794000 Open source
20202020-12-31	Free cash flow margin	-92.2%	Revenue: 57994000 Open source Operating Cash Flow: -49912000 Open source Capital Expenditure: 3585000 Open source
20212021-12-31	Free cash flow margin	-719.4%	Revenue: 33053000 Open source Operating Cash Flow: -225030000 Open source Capital Expenditure: 12756000 Open source
20222022-12-31	Free cash flow margin	-665.5%	Revenue: 52121000 Open source Operating Cash Flow: -333287000 Open source Capital Expenditure: 13558000 Open source
20232023-12-31	Free cash flow margin	-1,124.9%	Revenue: 36275000 Open source Operating Cash Flow: -394086000 Open source Capital Expenditure: 13985000 Open source
20242024-12-31	Free cash flow margin	-612.8%	Revenue: 57877000 Open source Operating Cash Flow: -348880000 Open source Capital Expenditure: 5778000 Open source
20252025-12-31	Free cash flow margin	-585%	Revenue: 67671000 Open source Operating Cash Flow: -394736000 Open source Capital Expenditure: 1129000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -394.7M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	36109000	Operating Cash Flow: 36109000 Open source
20172017-12-31	Operating cash flow	-65276000	Operating Cash Flow: -65276000 Open source
20182018-12-31	Operating cash flow	-61257000	Operating Cash Flow: -61257000 Open source
20192019-12-31	Operating cash flow	-103240000	Operating Cash Flow: -103240000 Open source
20202020-12-31	Operating cash flow	-49912000	Operating Cash Flow: -49912000 Open source
20212021-12-31	Operating cash flow	-225030000	Operating Cash Flow: -225030000 Open source
20222022-12-31	Operating cash flow	-333287000	Operating Cash Flow: -333287000 Open source
20232023-12-31	Operating cash flow	-394086000	Operating Cash Flow: -394086000 Open source
20242024-12-31	Operating cash flow	-348880000	Operating Cash Flow: -348880000 Open source
20252025-12-31	Operating cash flow	-394736000	Operating Cash Flow: -394736000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -395.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	29944000	Operating Cash Flow: 36109000 Open source Capital Expenditure: 6165000 Open source
20172017-12-31	Free cash flow	-75367000	Operating Cash Flow: -65276000 Open source Capital Expenditure: 10091000 Open source
20182018-12-31	Free cash flow	-67615000	Operating Cash Flow: -61257000 Open source Capital Expenditure: 6358000 Open source
20192019-12-31	Free cash flow	-110034000	Operating Cash Flow: -103240000 Open source Capital Expenditure: 6794000 Open source
20202020-12-31	Free cash flow	-53497000	Operating Cash Flow: -49912000 Open source Capital Expenditure: 3585000 Open source
20212021-12-31	Free cash flow	-237786000	Operating Cash Flow: -225030000 Open source Capital Expenditure: 12756000 Open source
20222022-12-31	Free cash flow	-346845000	Operating Cash Flow: -333287000 Open source Capital Expenditure: 13558000 Open source
20232023-12-31	Free cash flow	-408071000	Operating Cash Flow: -394086000 Open source Capital Expenditure: 13985000 Open source
20242024-12-31	Free cash flow	-354658000	Operating Cash Flow: -348880000 Open source Capital Expenditure: 5778000 Open source
20252025-12-31	Free cash flow	-395865000	Operating Cash Flow: -394736000 Open source Capital Expenditure: 1129000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

20.3% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	Total Assets: 298969000 Open source
2017-12-31	Liabilities / assets	Not reported	Total Assets: 376235000 Open source
2018-12-31	Liabilities / assets	Not reported	Total Assets: 347315000 Open source
2019-12-31	Liabilities / assets	Not reported	Total Assets: 334280000 Open source
2020-12-31	Liabilities / assets	Not reported	Total Assets: 676322000 Open source
2021-12-31	Liabilities / assets	Not reported	Total Assets: 1294464000 Open source
20222022-12-31	Liabilities / assets	18.7%	Total Liabilities: 284530000 Open source Total Assets: 1520114000 Open source
20232023-12-31	Liabilities / assets	19.3%	Total Liabilities: 250808000 Open source Total Assets: 1300977000 Open source
20242024-12-31	Liabilities / assets	26.8%	Total Liabilities: 319059000 Open source Total Assets: 1191015000 Open source
20252025-12-31	Liabilities / assets	20.3%	Total Liabilities: 170733000 Open source Total Assets: 842127000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.08× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	9.15×	Current Assets: 281306000 Open source Current Liabilities: 30730000 Open source
20172017-12-31	Current assets / current liabilities	11.32×	Current Assets: 354830000 Open source Current Liabilities: 31359000 Open source
20182018-12-31	Current assets / current liabilities	8.01×	Current Assets: 324977000 Open source Current Liabilities: 40572000 Open source
20192019-12-31	Current assets / current liabilities	8.12×	Current Assets: 289481000 Open source Current Liabilities: 35633000 Open source
20202020-12-31	Current assets / current liabilities	9.59×	Current Assets: 616517000 Open source Current Liabilities: 64254000 Open source
20212021-12-31	Current assets / current liabilities	6.11×	Current Assets: 769303000 Open source Current Liabilities: 125833000 Open source
20222022-12-31	Current assets / current liabilities	9.61×	Current Assets: 1216797000 Open source Current Liabilities: 126554000 Open source
20232023-12-31	Current assets / current liabilities	8.67×	Current Assets: 998330000 Open source Current Liabilities: 115208000 Open source
20242024-12-31	Current assets / current liabilities	5.77×	Current Assets: 639863000 Open source Current Liabilities: 110851000 Open source
20252025-12-31	Current assets / current liabilities	5.08×	Current Assets: 527711000 Open source Current Liabilities: 103884000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 31.63 million Exact value Exact value: -31634000 USD 2016-01-01 – 2016-12-31: -31634000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2016-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -31634000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31634000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459019004680/ntla-20181231.xml#107686 Filing: 000156459019004680 The citation records this snapshot. The page link may show a newer release later.	USD 36.11 million Exact value Exact value: 36109000 USD 2016-01-01 – 2016-12-31: 36109000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2016-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: 36109000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 36109000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459019004680/ntla-20181231.xml#135114 Filing: 000156459019004680 The citation records this snapshot. The page link may show a newer release later.	USD 6.17 million Exact value Exact value: 6165000 USD 2016-01-01 – 2016-12-31: 6165000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2016-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 6165000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6165000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459019004680/ntla-20181231.xml#135746 Filing: 000156459019004680 The citation records this snapshot. The page link may show a newer release later.	USD 29.94 million Calculation and evidence 36109000 − 6165000 USD Exact free cash flow: 29944000 USD 2016-01-01 – 2016-12-31: 36109000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 6165000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2016-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: 29944000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 36109000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459019004680/ntla-20181231.xml#135114 Filing: 000156459019004680 Input fundies:CapitalExpenditure: 6165000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459019004680/ntla-20181231.xml#135746 Filing: 000156459019004680 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 67.54 million Exact value Exact value: -67543000 USD 2017-01-01 – 2017-12-31: -67543000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2017-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -67543000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -67543000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459020007409/ntla-10k_20191231.htm#3288325 Filing: 000156459020007409 The citation records this snapshot. The page link may show a newer release later.	−USD 65.28 million Exact value Exact value: -65276000 USD 2017-01-01 – 2017-12-31: -65276000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2017-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -65276000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -65276000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459020007409/ntla-10k_20191231.htm#2225081 Filing: 000156459020007409 The citation records this snapshot. The page link may show a newer release later.	USD 10.09 million Exact value Exact value: 10091000 USD 2017-01-01 – 2017-12-31: 10091000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2017-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 10091000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10091000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459020007409/ntla-10k_20191231.htm#2235909 Filing: 000156459020007409 The citation records this snapshot. The page link may show a newer release later.	−USD 75.37 million Calculation and evidence -65276000 − 10091000 USD Exact free cash flow: -75367000 USD 2017-01-01 – 2017-12-31: -65276000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 10091000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2017-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -75367000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -65276000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459020007409/ntla-10k_20191231.htm#2225081 Filing: 000156459020007409 Input fundies:CapitalExpenditure: 10091000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459020007409/ntla-10k_20191231.htm#2235909 Filing: 000156459020007409 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 85.34 million Exact value Exact value: -85343000 USD 2018-01-01 – 2018-12-31: -85343000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2018-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -85343000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -85343000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459021009011/ntla-10k_20201231.htm#3277414 Filing: 000156459021009011 The citation records this snapshot. The page link may show a newer release later.	−USD 61.26 million Exact value Exact value: -61257000 USD 2018-01-01 – 2018-12-31: -61257000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2018-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -61257000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61257000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459021009011/ntla-10k_20201231.htm#2109964 Filing: 000156459021009011 The citation records this snapshot. The page link may show a newer release later.	USD 6.36 million Exact value Exact value: 6358000 USD 2018-01-01 – 2018-12-31: 6358000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2018-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 6358000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6358000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459021009011/ntla-10k_20201231.htm#2120818 Filing: 000156459021009011 The citation records this snapshot. The page link may show a newer release later.	−USD 67.62 million Calculation and evidence -61257000 − 6358000 USD Exact free cash flow: -67615000 USD 2018-01-01 – 2018-12-31: -61257000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 6358000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2018-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -67615000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61257000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459021009011/ntla-10k_20201231.htm#2109964 Filing: 000156459021009011 Input fundies:CapitalExpenditure: 6358000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000156459021009011/ntla-10k_20201231.htm#2120818 Filing: 000156459021009011 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 474.19 million Exact value Exact value: -474186000 USD 2019-01-01 – 2019-12-31: -474186000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2019-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -474186000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -474186000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017023004097/ntla-20221231.htm#4029395 Filing: 000095017023004097 The citation records this snapshot. The page link may show a newer release later.	−USD 103.24 million Exact value Exact value: -103240000 USD 2019-01-01 – 2019-12-31: -103240000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2019-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -103240000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -103240000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017022001981/ntla-20211231.htm#2288250 Filing: 000095017022001981 The citation records this snapshot. The page link may show a newer release later.	USD 6.79 million Exact value Exact value: 6794000 USD 2019-01-01 – 2019-12-31: 6794000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2019-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 6794000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6794000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017022001981/ntla-20211231.htm#2298330 Filing: 000095017022001981 The citation records this snapshot. The page link may show a newer release later.	−USD 110.03 million Calculation and evidence -103240000 − 6794000 USD Exact free cash flow: -110034000 USD 2019-01-01 – 2019-12-31: -103240000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 6794000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2019-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -110034000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -103240000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017022001981/ntla-20211231.htm#2288250 Filing: 000095017022001981 Input fundies:CapitalExpenditure: 6794000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017022001981/ntla-20211231.htm#2298330 Filing: 000095017022001981 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 134.23 million Exact value Exact value: -134231000 USD 2020-01-01 – 2020-12-31: -134231000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2020-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -134231000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -134231000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017023004097/ntla-20221231.htm#4033907 Filing: 000095017023004097 The citation records this snapshot. The page link may show a newer release later.	−USD 49.91 million Exact value Exact value: -49912000 USD 2020-01-01 – 2020-12-31: -49912000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2020-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -49912000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -49912000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017023004097/ntla-20221231.htm#2497638 Filing: 000095017023004097 The citation records this snapshot. The page link may show a newer release later.	USD 3.59 million Exact value Exact value: 3585000 USD 2020-01-01 – 2020-12-31: 3585000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2020-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 3585000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3585000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017023004097/ntla-20221231.htm#2508853 Filing: 000095017023004097 The citation records this snapshot. The page link may show a newer release later.	−USD 53.5 million Calculation and evidence -49912000 − 3585000 USD Exact free cash flow: -53497000 USD 2020-01-01 – 2020-12-31: -49912000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3585000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2020-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -53497000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -49912000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017023004097/ntla-20221231.htm#2497638 Filing: 000095017023004097 Input fundies:CapitalExpenditure: 3585000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017023004097/ntla-20221231.htm#2508853 Filing: 000095017023004097 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 267.89 million Exact value Exact value: -267892000 USD 2021-01-01 – 2021-12-31: -267892000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2021-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -267892000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -267892000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018736/ntla-20231231.htm#2931564 Filing: 000095017024018736 The citation records this snapshot. The page link may show a newer release later.	−USD 225.03 million Exact value Exact value: -225030000 USD 2021-01-01 – 2021-12-31: -225030000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2021-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -225030000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -225030000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018736/ntla-20231231.htm#1865709 Filing: 000095017024018736 The citation records this snapshot. The page link may show a newer release later.	USD 12.76 million Exact value Exact value: 12756000 USD 2021-01-01 – 2021-12-31: 12756000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2021-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 12756000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12756000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018736/ntla-20231231.htm#1872528 Filing: 000095017024018736 The citation records this snapshot. The page link may show a newer release later.	−USD 237.79 million Calculation and evidence -225030000 − 12756000 USD Exact free cash flow: -237786000 USD 2021-01-01 – 2021-12-31: -225030000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 12756000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2021-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -237786000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -225030000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018736/ntla-20231231.htm#1865709 Filing: 000095017024018736 Input fundies:CapitalExpenditure: 12756000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017024018736/ntla-20231231.htm#1872528 Filing: 000095017024018736 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 474.19 million Exact value Exact value: -474186000 USD 2022-01-01 – 2022-12-31: -474186000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2022-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -474186000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -474186000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017025029007/ntla-20241231.htm#3337883 Filing: 000095017025029007 The citation records this snapshot. The page link may show a newer release later.	−USD 333.29 million Exact value Exact value: -333287000 USD 2022-01-01 – 2022-12-31: -333287000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2022-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -333287000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -333287000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017025029007/ntla-20241231.htm#2048176 Filing: 000095017025029007 The citation records this snapshot. The page link may show a newer release later.	USD 13.56 million Exact value Exact value: 13558000 USD 2022-01-01 – 2022-12-31: 13558000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2022-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 13558000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13558000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017025029007/ntla-20241231.htm#2056819 Filing: 000095017025029007 The citation records this snapshot. The page link may show a newer release later.	−USD 346.85 million Calculation and evidence -333287000 − 13558000 USD Exact free cash flow: -346845000 USD 2022-01-01 – 2022-12-31: -333287000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 13558000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2022-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -346845000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -333287000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017025029007/ntla-20241231.htm#2048176 Filing: 000095017025029007 Input fundies:CapitalExpenditure: 13558000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000095017025029007/ntla-20241231.htm#2056819 Filing: 000095017025029007 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 481.19 million Exact value Exact value: -481192000 USD 2023-01-01 – 2023-12-31: -481192000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2023-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -481192000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -481192000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#3346251 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	−USD 394.09 million Exact value Exact value: -394086000 USD 2023-01-01 – 2023-12-31: -394086000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2023-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -394086000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -394086000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2038876 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	USD 13.99 million Exact value Exact value: 13985000 USD 2023-01-01 – 2023-12-31: 13985000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2023-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 13985000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13985000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2048112 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	−USD 408.07 million Calculation and evidence -394086000 − 13985000 USD Exact free cash flow: -408071000 USD 2023-01-01 – 2023-12-31: -394086000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 13985000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2023-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -408071000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -394086000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2038876 Filing: 000119312526076550 Input fundies:CapitalExpenditure: 13985000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2048112 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 519.02 million Exact value Exact value: -519021000 USD 2024-01-01 – 2024-12-31: -519021000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2024-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -519021000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -519021000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#3344503 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	−USD 348.88 million Exact value Exact value: -348880000 USD 2024-01-01 – 2024-12-31: -348880000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2024-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -348880000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -348880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2036985 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	USD 5.78 million Exact value Exact value: 5778000 USD 2024-01-01 – 2024-12-31: 5778000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2024-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 5778000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5778000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2046336 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	−USD 354.66 million Calculation and evidence -348880000 − 5778000 USD Exact free cash flow: -354658000 USD 2024-01-01 – 2024-12-31: -348880000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 5778000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2024-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -354658000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -348880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2036985 Filing: 000119312526076550 Input fundies:CapitalExpenditure: 5778000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2046336 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 412.69 million Exact value Exact value: -412694000 USD 2025-01-01 – 2025-12-31: -412694000 USD Inspect Net Income Open source Share or cite Citation for Net Income · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Net Income: -412694000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -412694000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#3342755 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	−USD 394.74 million Exact value Exact value: -394736000 USD 2025-01-01 – 2025-12-31: -394736000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Operating Cash Flow: -394736000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -394736000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2035094 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	USD 1.13 million Exact value Exact value: 1129000 USD 2025-01-01 – 2025-12-31: 1129000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Capital Expenditure: 1129000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1129000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2044560 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.	−USD 395.87 million Calculation and evidence -394736000 − 1129000 USD Exact free cash flow: -395865000 USD 2025-01-01 – 2025-12-31: -394736000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1129000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INTELLIA THERAPEUTICS, INC. · 2025-12-31 INTELLIA THERAPEUTICS, INC. (edgar:1652130) Free cash flow: -395865000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T04:05:57Z Snapshot: 62020116f14efe1821a44f9e6c385e2627dbbe64fd7a0027659ee04a173ab1a8 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1652130?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -394736000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2035094 Filing: 000119312526076550 Input fundies:CapitalExpenditure: 1129000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm#2044560 Filing: 000119312526076550 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

100 filings · 2,774 latest values · 2,774 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001652130, 1652130, NTLA, edgar:1652130

Also known as INTELLIA THERAPEUTICS, INC., INTELLIA THERAPEUTICS, INC., Intellia Therapeutics, Inc.

INTELLIA THERAPEUTICS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation